Renal Cell Carcinoma for USMLE Step 1
Start your One-Week Free Trial
Already subscribed? Log in »
Renal Cell Carcinoma for the USMLE Step 1 Exam
- Definition:
- Renal cell carcinoma (RCC) is the most common type of kidney cancer, arising from the renal tubular epithelium. RCC can be classified into several histologic subtypes, with clear cell RCC being the most prevalent.
- Epidemiology:
- RCC predominantly affects individuals aged 60-70 years and is more common in men. Key risk factors include:
- Smoking: Strongly linked to RCC.
- Obesity: Increases risk, particularly in women.
- Hypertension: Chronic hypertension is associated with increased risk.
- Genetic Syndromes:
- Von Hippel-Lindau (VHL) disease: Increases the risk of developing clear cell RCC due to mutations in the VHL gene.
- Chronic Kidney Disease (CKD): Prolonged dialysis and acquired cystic kidney disease increase RCC risk.
- Pathophysiology:
- RCC originates from the proximal renal tubular epithelium. Subtypes include:
- Clear Cell RCC: The most common, accounting for 75-85% of cases. It contains cells with clear or granular cytoplasm due to lipid and glycogen accumulation.
- Papillary RCC: Makes up 10-15% of cases and has two subtypes (type 1 and type 2).
- Chromophobe RCC: A rarer form, generally with a better prognosis.
- RCC often invades local structures such as the renal vein and can extend into the inferior vena cava (IVC). Metastasis to the lungs, bones, liver, and brain is common in advanced disease.
- Clinical Presentation:
- RCC is frequently asymptomatic in its early stages and may be discovered incidentally on imaging. The classic triad of symptoms is uncommon but includes:
- Hematuria: The most common presenting symptom.
- Flank Pain: Results from tumor growth and pressure on surrounding tissues.
- Palpable Abdominal Mass: Seen in advanced cases.
- Paraneoplastic Syndromes:
- RCC is known for producing paraneoplastic syndromes, including:
- Hypercalcemia: Due to increased parathyroid hormone-related protein (PTHrP).
- Polycythemia: From erythropoietin production by the tumor.
- Hypertension: Due to increased renin secretion.
- Diagnosis:
- Imaging:
- CT Scan: The gold standard for diagnosing RCC. It distinguishes solid from cystic masses and assesses tumor extension into surrounding structures.
- MRI: Used for evaluating venous involvement or when radiation exposure is a concern (e.g., pregnant patients).
- Urinalysis: Detects hematuria, but is nonspecific for RCC.
- Biopsy: Usually not needed if imaging is typical of RCC, but it can be performed for indeterminate masses.
- Staging:
- RCC is staged using the TNM system:
- Stage I: Tumor confined to the kidney, ≤7 cm.
- Stage II: Tumor >7 cm, still confined to the kidney.
- Stage III: Tumor extends into major veins or perinephric tissues.
- Stage IV: Tumor invades adjacent organs or distant metastasis is present.
- Management:
- Surgical Treatment:
- Radical Nephrectomy: The removal of the kidney, adrenal gland, and surrounding fat is the standard treatment for localized RCC.
- Partial Nephrectomy: Preferred for small tumors (<4 cm) or in patients with a solitary kidney to preserve renal function.
- Systemic Therapy:
- For advanced or metastatic RCC, targeted therapies (e.g., tyrosine kinase inhibitors like sunitinib) and immune checkpoint inhibitors (e.g., nivolumab) are the mainstays of treatment.
- Ablative Therapies:
- Radiofrequency ablation (RFA) or cryoablation may be used in patients who are not surgical candidates.
- Prognosis:
- Prognosis is highly dependent on the stage at diagnosis. Localized RCC has a favorable prognosis, with 5-year survival rates >90%. Metastatic disease, however, has a poor prognosis, with a 5-year survival rate of 10-20%.
Key Points
- Renal cell carcinoma (RCC) is the most common kidney cancer, with clear cell RCC being the predominant subtype.
- Risk factors include smoking, obesity, hypertension, and genetic syndromes like Von Hippel-Lindau disease.
- RCC often presents asymptomatically but may manifest with hematuria, flank pain, and a palpable abdominal mass in advanced cases.
- Imaging, particularly CT scans, is essential for diagnosis and staging, while biopsy is typically reserved for indeterminate cases.
- Surgical resection (radical or partial nephrectomy) is the main treatment for localized RCC. Systemic therapies, including targeted agents and immune checkpoint inhibitors, are used for metastatic disease.
- Prognosis depends on stage, with localized disease having a favorable outlook and metastatic disease associated with poor survival outcomes.